Literature DB >> 7477195

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

J C Roujeau1, J P Kelly, L Naldi, B Rzany, R S Stern, T Anderson, A Auquier, S Bastuji-Garin, O Correia, F Locati.   

Abstract

BACKGROUND: Toxic epidermal necrolysis and Stevens-Johnson syndrome are rare, life-threatening, drug-induced cutaneous reactions. We conducted a case-control study to quantify the risks associated with the use of specific drugs.
METHODS: Data were obtained through surveillance networks in France, Germany, Italy, and Portugal. Drug use before the onset of disease was compared in 245 people who were hospitalized because of toxic epidermal necrolysis or Stevens-Johnson syndrome and 1147 patients hospitalized for other reasons (controls). Crude relative risks were calculated and adjusted for confounding by multivariate methods when numbers were large enough.
RESULTS: Among drugs usually used for short periods, the risks were increased for trimethoprim-sulfamethoxazole and other sulfonamide antibiotics (crude relative risk, 172; 95 percent confidence interval, 75 to 396), chlormezanone (crude relative risk, 62; 21 to 188), aminopenicillins (multivariate relative risk, 6.7; 2.5 to 18), quinolones (multivariate relative risk, 10; 2.6 to 38), and cephalosporins (multivariate relative risk, 14; 3.2 to 59). For acetaminophen, the multivariate relative risk was 0.6 (95 percent confidence interval, 0.2 to 1.3) in France but 9.3 (3.9 to 22) in the other countries. Among drugs usually used for months or years, the increased risk was confined largely to the first two months of treatment, when crude relative risks were as follows: carbamazepine, 90 (95 percent confidence interval, 19 to infinity); phenobarbital, 45 (19 to 108); phenytoin, 53 (11 to infinity); valproic acid, 25 (4.3 to infinity); oxicam nonsteroidal antiinflammatory drugs (NSAIDs), 72 (25 to 209); allopurinol, 52 (16 to 167); and corticosteroids, 54 (23 to 124). For many drugs, including thiazide diuretics and oral hypoglycemic agents, there was no significant increase in risk.
CONCLUSIONS: The use of antibacterial sulfonamides, anticonvulsant agents, oxicam NSAIDs, allopurinol, chlormezanone, and corticosteroids is associated with large increases in the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. But for none of the drugs does the excess risk exceed five cases per million users per week.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477195     DOI: 10.1056/NEJM199512143332404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  238 in total

1.  Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions.

Authors:  L Naldi; A Conforti; M Venegoni; M G Troncon; A Caputi; E Ghiotto; A Cocci; U Moretti; G Velo; R Leone
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Antimicrobial prophylaxis.

Authors:  J Smith; A Finn
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

Review 3.  Hypersensitivity to pyrazolones.

Authors:  M Levy
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

4.  Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan.

Authors:  Kow-Tong Chen; Shiing-Jer Twu; Hong-Jen Chang; Ruey-Shiung Lin
Journal:  Am J Public Health       Date:  2003-03       Impact factor: 9.308

Review 5.  Bendamustine for treatment of chronic lymphocytic leukemia.

Authors:  Julie Elizabeth Chang; Brad Steven Kahl
Journal:  Expert Opin Pharmacother       Date:  2012-06-05       Impact factor: 3.889

6.  Adverse effects of observational studies when examining adverse outcomes of drugs: case-control studies with low prevalence of exposure.

Authors:  Peter C Austin; Muhammad Mamdani; Ivan J Williams
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

8.  Large-scale elucidation of drug response pathways in humans.

Authors:  Yael Silberberg; Assaf Gottlieb; Martin Kupiec; Eytan Ruppin; Roded Sharan
Journal:  J Comput Biol       Date:  2012-02       Impact factor: 1.479

9.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

Review 10.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.